No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
GERN Geron
- 4.600
- -0.070-1.50%
Close Jul 19 16:00 ET
- 4.601
- +0.001+0.02%
Post 19:30 ET
2.73BMarket Cap-13529P/E (TTM)
4.765High4.590Low4.16MVolume4.685Open4.670Pre Close19.41MTurnover0.81%Turnover RatioLossP/E (Static)593.13MShares5.34052wk High7.92P/B2.37BFloat Cap1.64052wk Low--Dividend TTM515.43MShs Float75.875Historical High--Div YieldTTM3.75%Amplitude0.750Historical Low4.661Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024
Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the market opens on Thursday,
Institutional Investors Control 61% of Geron Corporation (NASDAQ:GERN) and Were Rewarded Last Week After Stock Increased 5.5%
Key Insights Given the large stake in the stock by institutions, Geron's stock price might be vulnerable to their trading decisions 51% of the business is held by the top 14 shareholders
Geron(GERN.US) Officer Sells US$3.07 Million in Common Stock
$Geron(GERN.US)$ Officer GRETHLEIN ANDREW J sold 674.35K shares of common stock on Jul 8, 2024 at an average price of $4.557 for a total value of $3.07 million.Source: Announcement What is statement
Form 144 | Geron(GERN.US) Officer Proposes to Sell 2.93 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 8, $Geron(GERN.US)$、$GERON CORP C/WTS 31/12/2025 (TO SUB FOR ORD)(GERNW.US)$ Officer GRETHLEIN ANDREW J intends to sell 674.35K shares of its common stock on Jul 8, with a
Wuchan Zhongda Geron Anticipates 56% to 66% Higher Net Profit in H1; Shares Rise 6%
Wuchan Zhongda Geron (SHE:002722) anticipated its attributable net profit to reach 80 million yuan to 85.2 million yuan in the first half of the year, a 56% to 66% increase from the 51.2 million yuan
Wuchan Zhongda Geron Co.,Ltd. (SZSE:002722) Pays A CN¥0.19 Dividend In Just Three Days
Wuchan Zhongda Geron Co.,Ltd. (SZSE:002722) stock is about to trade ex-dividend in 3 days. Typically, the ex-dividend date is one business day before the record date which is the date on which a comp
Comments
3
Barclays Initiates Coverage On Geron Corporation with Overweight Rating, Announces Price Target of $9.
On June 2, 2024, Barclays initiated coverage of Geron Corporation (NasdaqGS:GERN) with an Overweight rating, setting a price target of $9. At the time of this announcement, Geron’s stock was trading at $4.83, indicating a bullish sentiment from Barclays and predicting significant potential upside for investors. $Geron(GERN.US$
https://stockregion.app/p/investment-bank-initiates-overweight
On June 2, 2024, Barclays initiated coverage of Geron Corporation (NasdaqGS:GERN) with an Overweight rating, setting a price target of $9. At the time of this announcement, Geron’s stock was trading at $4.83, indicating a bullish sentiment from Barclays and predicting significant potential upside for investors. $Geron(GERN.US$
https://stockregion.app/p/investment-bank-initiates-overweight
🚨 1 AdCom & 3 PDUFA decisions this week:
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : 🤔
⇨ Elafibranor
‣ Primary biliary cholangitis
‣ PDUFA date: 6/10/24
$Regeneron Pharmaceuticals(REGN.US$ : 🤔
⇨ Kevzara (sarilumab)
‣ Polyarticular juvenile idiopathic arthritis
‣ PDUFA date: 6/10/24
$Bristol-Myers Squibb(BMY.US$ : 🤔
⇨ Augtyro™ (Repotrectinib)
‣ PDUFA date: 6/15/24 (sNDA)
🗓️ Last week’s PDUFAs:
$GlaxoSmithKline(GSK.US$ : Approved 6/7 🎉
⇨ Arexvy
‣ Respiratory s...
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : 🤔
⇨ Elafibranor
‣ Primary biliary cholangitis
‣ PDUFA date: 6/10/24
$Regeneron Pharmaceuticals(REGN.US$ : 🤔
⇨ Kevzara (sarilumab)
‣ Polyarticular juvenile idiopathic arthritis
‣ PDUFA date: 6/10/24
$Bristol-Myers Squibb(BMY.US$ : 🤔
⇨ Augtyro™ (Repotrectinib)
‣ PDUFA date: 6/15/24 (sNDA)
🗓️ Last week’s PDUFAs:
$GlaxoSmithKline(GSK.US$ : Approved 6/7 🎉
⇨ Arexvy
‣ Respiratory s...
9
1
$Geron(GERN.US$
This could get interesting considering the short stats.
2.85 days to cover. 10.46% short floats.
This could get interesting considering the short stats.
2.85 days to cover. 10.46% short floats.
1
Geron Announces FDA Approval of RYTELO™ (Imetelstat) for Lower-Risk MDS with Transfusion-Dependent Anemia.
On June 7, 2024, Geron Corporation, a commercial-stage biopharmaceutical company, proudly announced that the U.S. Food and Drug Administration (FDA) has approved RYTELO™ (imetelstat), marking a milestone in the treatment of adult patients with lower-risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia. This ...
On June 7, 2024, Geron Corporation, a commercial-stage biopharmaceutical company, proudly announced that the U.S. Food and Drug Administration (FDA) has approved RYTELO™ (imetelstat), marking a milestone in the treatment of adult patients with lower-risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia. This ...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg